NYSEAMERICAN:PLXProtalix Biotherapeutics Stock Price, Forecast & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Protalix Biotherapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Protalix Biotherapeutics.

Protalix Biotherapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020.
View our earnings forecast for Protalix Biotherapeutics.

Protalix Biotherapeutics will be holding an earnings conference call on Monday, August 10th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) announced its quarterly earnings data on Monday, June, 1st. The company reported $0.10 earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.40. The firm had revenue of $21.65 million for the quarter, compared to the consensus estimate of $6.60 million. During the same period last year, the company posted ($0.50) earnings per share.
View Protalix Biotherapeutics' earnings history.

Protalix Biotherapeutics's stock reverse split on the morning of Friday, December 20th 2019. The 1-10 reverse split was announced on Monday, December 9th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, December 19th 2019. An investor that had 100 shares of Protalix Biotherapeutics stock prior to the reverse split would have 10 shares after the split.

1 brokerages have issued 12-month price targets for Protalix Biotherapeutics' shares. Their forecasts range from $11.00 to $11.00. On average, they anticipate Protalix Biotherapeutics' share price to reach $11.00 in the next twelve months. This suggests a possible upside of 205.6% from the stock's current price.
View analysts' price targets for Protalix Biotherapeutics.

News coverage about PLX stock has been trending somewhat negative this week, according to InfoTrie Sentiment. The research firm rates the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Protalix Biotherapeutics earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 5.0 out of 10, meaning that recent media coverage is somewhat likely to have an impact on the company's share price in the near term.
View the latest news about Protalix Biotherapeutics.

Protalix Biotherapeutics saw a decline in short interest in July. As of July 15th, there was short interest totaling 355,100 shares, a decline of 22.6% from the June 30th total of 458,600 shares. Based on an average trading volume of 231,500 shares, the days-to-cover ratio is presently 1.5 days. Approximately 1.5% of the company's shares are short sold.
View Protalix Biotherapeutics' Current Options Chain.

Some companies that are related to Protalix Biotherapeutics include Biotest (BIO), IMV (IMV), Neptune Wellness Solutions (NEPT), Inventiva (IVA), Silence Therapeutics (SLN), TELIX Pharmaceutical (TLX), Starpharma (SPL), Tiziana Life Sciences (TILS), IMV (IMV), ProMetic Life Sciences (PLI), Synairgen (SNG), Fennec Pharmaceuticals (FRX), Verona Pharma (VRP), Ergomed (ERGO) and Pfenex (PFNX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Protalix Biotherapeutics investors own include Brainstorm Cell Therapeutics (BCLI), Pluristem Therapeutics (PSTI), Crispr Therapeutics (CRSP), Agile Therapeutics (AGRX), Sangamo Therapeutics (SGMO), Anavex Life Sciences (AVXL), VBI Vaccines (VBIV), Amarin (AMRN), BIOLINERX LTD/S (BLRX) and Nabriva Therapeutics (NBRV).

Protalix Biotherapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PLX."

Protalix Biotherapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Psagot Investment House Ltd. (1.45%).
View institutional ownership trends for Protalix Biotherapeutics.

PLX stock was acquired by a variety of institutional investors in the last quarter, including Psagot Investment House Ltd..
View insider buying and selling activity for Protalix Biotherapeutics.

Shares of PLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PLX stock can currently be purchased for approximately $3.60.

Protalix Biotherapeutics has a market capitalization of $116.79 million. Protalix Biotherapeutics employs 184 workers across the globe.

The official website for Protalix Biotherapeutics is www.protalix.com.

Protalix Biotherapeutics' mailing address is 2 Snunit St, Science Park, Pob 455, KARMIEL, 20100, Israel. The company can be reached via phone at +972-4-9028100.